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Abstract The prevalence, complexity, clinical importance, heterogeneity and unpredictability
of inherited cardiovascular diseases make the development of inherited cardiovascular disease
centers an inevitability, with the ultimate goal of reducing the morbidity and mortality associ-
ated with these conditions. An inherited cardiovascular disease center may be seen as a subunit
of a cardiology department, with health professionals specializing in these types of disorders,
organized to provide excellence in all related areas, including diagnosis, treatment, follow-
up, prevention, risk stratiﬁcation and prognosis. Among its objectives are the development of
action protocols and the creation of databases that enable patients to be included in national
and international research networks. To achieve these objectives these centers should include
functional units of clinical and basic sciences, research, training and education, acting in har-
mony in a holistic approach to patients and their families. As most experience on inherited
cardiovascular diseases is based on hypertrophic cardiomyopathy and on ‘‘hypertrophic car-
diomyopathy centers’’, these centers represent an excellent opportunity to learn how to set
up inherited cardiovascular disease centers. European centers will differ from country to coun-
try, reﬂecting the heterogeneity of national health systems, but will share a common core,
presented in this document. Though we are aware that this ambitious project is not at all easy
and may be difﬁcult to implement in its entirety -- in fact we consider it a major step -- our
loaded from http://www.elsevier.pt, day 14/08/2012. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.position is that all the efforts to achieve it are worthwhile, considering that the main goal will
always be the well-being of those affected by these particular disorders.
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reserved.
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PALAVRAS-CHAVE
Doenc¸as cardíacas
hereditárias;
Unidades de doenc¸as
cardíacas
hereditárias;
Miocardiopatia
hipertróﬁca;
Centros de
miocardiopatia
hipertróﬁca
Dos centros de miocardiopatia hipertróﬁca até às unidades de doenc¸as cardíacas
hereditárias na Europa: um pequeno grande passo?
Resumo A prevalência, complexidade, importância clínica, heterogeneidade e imprevisibili-
dade das doenc¸as cardíacas heredofamiliares torna a criac¸ão de Unidades de Doenc¸as Cardíacas
Hereditárias uma inevitabilidade, cujo objectivo ﬁnal é reduzir a morbilidade e a mortalidade
relacionadas com estas patologias. Uma Unidade de Doenc¸as Cardíacas Hereditárias é uma
subunidade de um departamento de Cardiologia constituída por proﬁssionais de saúde espe-
cializados neste tipo de doenc¸as, organizado de forma a proporcionar a excelência em todos as
suas áreas, incluindo diagnóstico, tratamento, seguimento, prevenc¸ão, estratiﬁcac¸ão de risco e
determinac¸ão de prognóstico. Alguns dos seus objectivos são o desenvolvimento de protocolos
de actuac¸ão e a criac¸ão de bases de dados que permitam a inclusão de doentes em registos
e redes de investigac¸ão nacionais e internacionais. Para atingir estes objectivos estes centros
devem integrar Unidades Funcionais (clínica, ciências básicas, investigac¸ão, treino e educac¸ão),
actuando harmonicamente numa abordagem holística de doentes e suas famílias. Como grande
parte do conhecimento referente às doenc¸as cardíacas hereditárias se baseia na miocardiopa-
tia hipertróﬁca e na experiência adquirida com os ‘‘centros de miocardiopatia hipertróﬁca’’,
estes representam um excelente modelo para aprender como criar e desenvolver as Unidades
de Doenc¸as Cardíacas Hereditárias. A nível Europeu, as características destas Unidades serão
diferentes de um país para outro, reﬂectindo a heterogeneidade dos diferentes sistemas e
servic¸os nacionais de saúde, compartilhando no entanto um core comum, apresentado neste
documento. Embora conscientes de que este projecto é ambicioso e de que a sua concretizac¸ão
como um todo não será uma tarefa fácil, consideramos a aplicac¸ão e divulgac¸ão deste conceito
a nível nacional e Europeu um passo de grande importância. Assim, a nossa posic¸ão é que todos
os esforc¸os para atingir esta meta valem a pena, considerando que o principal objectivo será
sempre o bem-estar dos doentes afectados por estas patologias.
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ntroduction
any of the inherited cardiovascular diseases are uncom-
on, but collectively they represent a substantial burden
f disease, causing sudden cardiac death, heart failure
nd thromboembolism in many young people and adults in
urope every year. Many of these deaths can be prevented if
imely diagnosis and expert management of these patients
ecome standard practice across the continent.
Recent knowledge of the genetic basis of many of
hese conditions represents a turning-point in our approach,
nabling their detection in asymptomatic or mildly symp-
omatic individuals. With genetic testing, although it may
ot be possible to prevent all sudden cardiac deaths caused
y inherited diseases, many families could be spared the
rauma of multiple deaths among their members. Moreover,
he use of genetic tests (as opposed to conventional clinical
urveillance) can reduce costs, because family members who
o not carry the mutation can be discharged from follow-up.
Due to its higher prevalence and media impact, for a long
ime attention has been mainly focused on hypertrophic car-
iomyopathy (HCM) and on HCM centers, but the general
rend today is towards the development of inherited cardio-
ascular disease (ICVD) centers, specializing in a range of
isorders rather than in a single one, with higher beneﬁt-to-
ost ratios.
European ICVD units will differ in each country, reﬂect-
ng the heterogeneity of national health systems, but they
hould share a common core, as suggested in this document.
The unifying theme for these ICVD centers is the need
or an accurate genetic diagnosis that, along with thorough
M
e
sde Cardiologia. Publicado por Elsevier España, S.L. Todos os
ardiological investigation, will help provide management,
ounseling and advice for patients and their families. This
equires not only the integration of cardiology and genetics
ut also the development of shared care between cardio-
ogical and non-cardiological departments, with appropriate
eferrals from primary care.
Five main categories of inherited cardiovascular condi-
ions can be considered1:
. Arrhythmic syndromes (long and short QT syndromes,
Brugada syndrome, catecholaminergic polymorphic ven-
tricular tachycardia)
. Cardiomyopathies (hypertrophic, dilated, restrictive,
others)
. Arteriopathies (Marfan, Ehlers-Danlos, others)
. Muscular dystrophies (Emery-Dreifuss muscular dystro-
phy, myotonic dystrophy, others)
. Familial hypercholesterolemia.
The ICVD centers would only include categories 1 to 4,
s familial hypercholesterolemia is usually managed in spe-
ialist lipid clinics, with speciﬁc organizational and support
rrangements.
he paradigm of hypertrophic cardiomyopathyost of the experience on inherited cardiovascular dis-
ases is centered on hypertrophic cardiomyopathy and on
o-called ‘‘hypertrophic cardiomyopathy centers’’.
From hypertrophic cardiomyopathy centers to inherited cardiovascular disease centers in Europe 831
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Figure 1 The ‘‘uncommon’’ diseases.
As HCM is the most common and best-studied inher-
ited cardiovascular disease, sharing most of the problems
faced by other inherited heart conditions, HCM centers
represent an excellent case-study to learn how to set
up inherited cardiovascular disease centers. A thorough
knowledge of HCM and its centers is thus essential to this
subject.
Hypertrophic cardiomyopathy has a prevalence of about
0.2%2 (1 in 500 individuals), and is thus much more com-
mon than other chronic diseases (including cystic ﬁbrosis,
multiple sclerosis, amyotrophic lateral sclerosis and Mar-
fan syndrome) (Fig. 1). Unlike HCM, these diseases are
classiﬁed as rare (deﬁned as affecting less than 1 in 2000
individuals), with a special status, including speciﬁc insti-
tutional cooperation and support3,4. However, although not
having the status of a rare disease, HCM patients face
many of the difﬁculties associated with these conditions,
such as delayed diagnosis, lack of prospective evaluation
of the effectiveness of different therapeutic modalities,
and limited access to advanced diagnosis and treatment
methods.
The ﬁrst HCM center was established nearly 20 years
ago at the Royal Prince Alfred Hospital in Sydney, Australia.
Later, other centers were opened in Europe (Hammer-
smith Hospital, London, UK) and in the United States (NIH,
Bethesda, Maryland) 5. At present, there are numerous HCM
centers, in North America (US and Canada), Europe (Italy,
Germany, Ireland), the Middle East (Israel) and Asia (China).
Currently, some of the main centers are located in Minneapo-
lis (USA), London (UK) and Italy.
The clinical importance of HCM stems from two facts: it is
a major cause of sudden death -- an incidence of about 0.5%
per year, versus about 0.1% per year in the general pop-
ulation -- particularly in young populations; secondly, the
disease is an important cause of heart failure and throm-
boembolic phenomena associated with signiﬁcant morbidity
and mortality, more frequently in older patients (Fig. 2) 6,7.
Hypertrophic cardiomyopathy in Europe
In 2009, using a deﬁnition that includes the whole of the
transcontinental countries of Russia and Turkey8, the popu-
lation of Europe was about 830.4 million (slightly more than
13% of the world population). The exact ﬁgure depends on
the deﬁnition of the geographic extent of Europe, as in 2008
t
e
e
aFigure 2 Mode of HCM death according to age.3
he population of the EU was 499 million, non-EU countries in
urope accounted for another 94 million, and ﬁve transcon-
inental countries totaled 240 million people, half of whom
eside in Europe8,9.
On the basis of the prevalence mentioned above, there
ay be about 1660000 HCM patients in Europe. Of these,
ssuming that only 10-20% (166000 to 332000) are diagnosed,
bout 1328000 to 1494000 HCM patients are still undiag-
osed (80-90% of the HCM population) and are therefore
ithout the beneﬁt of preventive and/or therapeutic mea-
ures to avoid sudden death or other complications of the
isease.
Considering only this group of undiagnosed patients,
etween 6640 to 7470 patients (0.5% per year) will die sud-
enly every year in Europe without even knowing they have
he disease and with no prior medical intervention. More-
ver, these calculations can (and should) also be applied
o individual countries (Table 1). Using the above ﬁgures
or HCM prevalence and sudden death incidence, it can be
stimated that a country with a relatively small population
10 million) will have about 20 000 inhabitants with HCM,
ost of them undiagnosed, with more than 75 patients per
ear at risk of sudden cardiac death, with no prior diagno-
is or access to risk stratiﬁcation and prevention. Applying
hese calculations to countries with much larger populations
Table 1) the tremendous impact of failure to diagnose this
isease becomes obvious.
enters of reference and expertise1,10,11
lthough the concept of centers of reference, or centers of
xpertise, is somewhat ill-deﬁned, they may be described as
he ideal places for referring particular groups of patients.
hese centers centralize both expertise and services, bring-
ng together a group of multidisciplinary hospital-based
ompetences, organized around highly specialized medical
eams.
The ability to provide a comprehensive and effective
ervice is grounded ﬁrstly in the individual expertise and
xperience of the professionals involved; secondly in easy
ccess to specialized research; thirdly in their coming
ogether as a multidisciplinary team; and ﬁnally, in the
ffectiveness of the team’s working organization in deliv-
ring a highly speciﬁc care program. The creation of such
center requires more than simply a collection of experts
832 N. Cardim et al.
Table 1 Population of European countries (http://pt.wikipedia.org/wiki/Europe)
Country Population Country Population
Russia 141 950 000 Georgia 4 661 473
Germany 82 210 000 Croatia 4 551 000
Turkey 71 517 100 Ireland 4 234 925
France 65 073 482 Moldova 4 148 000
United Kingdom 61 113 205 Bosnia and Herzegovina 3 907 000
Italy 59 337 888 Lithuania 3 596 617
Spain 46 661 950 Armenia 3 229 900
Ukraine 46 398 114 Albania 3 130 000
Poland 38 115 967 Latvia 2 290 237
Romania 22 329 977 Macedonia 2 034 000
Netherlands 16 402 414 Slovenia 2 011 070
Kazakhstan 15 217 711 Estonia 1 332 893
Greece 11 147 000 Cyprus 818 200
Portugal 10 707 924 Montenegro 620 145
Czech Republic 10 501 197 Luxembourg 468 571
Belgium 10 445 852 Malta 402 668
Hungary 10 076 000 Iceland 304 334
Belarus 9 755 000 Jersey (UK crown dependency) 87 186
Serbia 9 465 507 Isle of Man (UK crown dependency) 77 000
Sweden 9 234 209 Andorra 67 000
Azerbaijan 8 621 000 Guernsey (UK crown dependency) 62 101
Austria 8 206 524 Faroe Islands (Denmark) 47 000
Bulgaria 7 761 000 Liechtenstein 35 000
Switzerland 7 252 000 Monaco 35 000
Slovakia 5 431 363 San Marino 28 000
Denmark 5 415 978 Gibraltar (United Kingdom) 28 000
Finland 5 261 008 Åland Islands (Finland) 26 771
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rom different disciplines. Rather, these centers should
nsure that the needs of the whole population with regard
o a speciﬁc condition are met and that patients and fam-
lies are managed holistically, with the most efﬁcient and
ffective use of resources10,11.
As agreed by international institutions1,10,11, the fol-
owing eight criteria should deﬁne a center of refer-
nce/expertise:
. appropriate capacities to diagnose, follow and manage
patients, with evidence of good outcomes;
. attractiveness, measured through volume of activity,
which needs to be signiﬁcantly larger than anticipated
from the prevalence of the diseases in question and the
catchment area (deﬁned as the geographical area served
by the hosting hospital for non-rare diseases) or national
coverage;
. the ability to provide expert advice on diagnosis and
management;
. the ability to produce and adhere to good practice guide-
lines and to implement outcome measures and quality
control;
. demonstration of a multidisciplinary approach;. a high level of expertise and experience documented
through publications, grants or honorary positions,
teaching and training;
. a strong contribution to research;
t
o
f
iican City 821
. close links and collaboration with other expert centers
at national and international level and the ability to net-
work.
The advantage of these centers lies in the fact that they
ot only provide a rating scheme that enables patients to
dentify the appropriate health care resources for their dis-
ase but also enable health care managers to identify where
est to allocate speciﬁc ﬁnancial resources in order to sup-
ort the additional activities linked to their duties.
ationale for the creation of ICVD centers
here are four major issues that increase the need for ICVD
enters:
First, as the number of patients with inherited cardiovas-
ular diseases is relatively small compared to the majority
f patients seen in general cardiology consultations (most
f whom have coronary, hypertensive or valvular heart dis-
ase), the experience of most clinical cardiologists in these
iseases is relatively limited. The general trend is thus for
nowledge of these common diseases to be extrapolated
o the management of patients with ICVD, an approach
hat is often unsuitable and sometimes actually danger-
us, given the speciﬁcity and complexity of the problems
aced by those with these conditions. Second, as research
n this area is in constant and rapid evolution, the non-expert
diovascular disease centers in Europe 833
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in ICVD is often confused by the ﬂood of data coming
from the medical literature. Third, the complex pathophys-
iology of ICVD requires a wide range of knowledge and
cooperation between different scientiﬁc areas and medical
subspecialties, including genetics, molecular biology, heart
failure, arrhythmias, myocardial ischemia, valvular disease,
thromboembolism, cardiac imaging, hemodynamics, inter-
ventional cardiology, and cardiac surgery. Finally, there is
a crucial need to standardize diagnostic and therapeutic
approaches through the development of protocols and the
creation of databases, which are essential for the develop-
ment of research projects.
Inherited cardiovascular disease centers1,10,11
An ICVD center may be considered a subunit of a cardiology
department composed of clinicians and health profession-
als experienced in ICVD, organized to ensure an approach
of excellence, according to the state of the art, in all
areas of these diseases. This approach should cover diag-
nosis, treatment, follow-up, prevention, risk stratiﬁcation
and determination of prognosis, and ideally also include a
strong component of basic and advanced research.
In these centers, patients with inherited cardiovascular
conditions will be followed in specialized consultations with
speciﬁc protocols, in which genotypic and phenotypic eval-
uation of the disease is performed, assessing not only the
patient but also his or her family.
This type of systematic approach to speciﬁc diseases,
concentrating large numbers of patients with the same dis-
order in referral centers, can have a signiﬁcant impact on
morbidity and mortality. This has been demonstrated for pul-
monary hypertension and cystic ﬁbrosis, in which increased
survival and better quality of life for affected patients have
been observed since this strategy was implemented through-
out the world3,4.
Objectives
The main objectives of ICVD centers are:
1. to provide clinical activity of excellence, according to
the state of the art, to ICVD patients and their fam-
ilies (including the above-mentioned close interaction
between cardiology and genetics);
2. to create core research in ICVD;
3. to train new clinicians and researchers with special
expertise in ICVD;
4. to contribute to education and awareness concerning
ICVD in the scientiﬁc community, society, government,
and the pharmaceutical and device industry, in order to
disseminate knowledge of the diseases and their multiple
and complex problems, with the objective of obtaining
institutional and non-institutional support for patients
and of developing credible research projects in this area.
Organizational issues1,10,11Organization is a key issue in achieving the above objectives.
An ICVD center should have a director and ﬁve func-
tional units (clinical, basic sciences, research, training, andFigure 3 Organization of ICVD centers.
ducation and awareness) (Fig. 3), closely inter-related and
ith extensive overlapping areas. It should be located in
major tertiary center, and be accessible to all its catch-
ent population. In small countries, such a center could be
ational in scope, with links to all regions of the country
with peripheral clinics or satellite centers).
) Director: with clinical expertise in ICVD and a background
in cardiac imaging;
) Functional Units: each with speciﬁc subdivisions.
linical unit
) Multidisciplinary clinical team. This team will include
a number of specialists from different areas, not only
from clinical cardiology (adult and pediatric consultants)
and genetics (clinical geneticists and genetic counselors)
but also consultants from other medical specialties
(including neurology, ophthalmology, internal medicine,
psychiatry, and clinical psychology) and specialists from
other areas (nutrition, nursing, and social support). As
mentioned above, the interaction between cardiology
and clinical genetics plays a key role in this unit. It is
current practice, whenever possible, to perform genetic
(rather than clinical) cascade screening, a cost-effective
model which enables family members to be identiﬁed as
not being at risk and so to be discharged from follow-up,
or identiﬁed as mutation carriers and hence requiring
follow-up.
) Multimodality imaging and electrocardiology department
with the ability to perform rest and exercise ECG,
echocardiography, cardiac magnetic resonance imaging
and cardiac computed tomography (with collaboration
between cardiology and radiology teams).
) Arrhythmology and electrophysiology department, meet-
ing patients’ speciﬁc needs such as electrophysiological
studies, ablation procedures or device implantation
(pacemakers, resynchronization devices and implantable
cardioverter-deﬁbrillators).
) Catheterization and interventional cardiology depart-
ment, providing diagnostic data (such as coronary and
aortic angiography) and therapeutic procedures (alco-
hol septal ablation, coronary intervention), working in
concert with the cardiac surgery department.
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) Cardiac surgery department with the ability to provide
all types of cardiovascular surgery, including major aortic
surgery, myectomy and valve surgery.
asic sciences unit
n ICVD center should have easy access not only to a cer-
iﬁcated laboratory or institute of molecular genetics and
olecular biology but also to a cardiovascular pathology
epartment. Ideally, the basic sciences unit should work in
lose cooperation with the clinical team.
esearch unit
his functional unit will focus on basic, translational and
linical research, promoting the interface between clinical
nd basic sciences for appropriate translation of knowledge.
articipation in clinical trials under strict ethical rules is
esirable in an ICVD center. The high level of expertise and
xperience of the centers should be documented through
ublications, grants, honorary positions, teaching and train-
ng. Involvement in epidemiological surveillance such as
egistries is recommended. The unit should have the ability
o produce and adhere to good practice guidelines. Coop-
ration between centers in different countries should be
avored through European reference networks. All projects
hould be approved by local (institutional) ethics commit-
ees.
raining unit
haring of knowledge between and within different special-
ies is central to the aims of this unit. Providing training
or health professionals should be a major goal, consider-
ng in particular the speciﬁc and often complex knowledge
equired in an ICVD center.
ducation and awareness unit
he team should be aware of the importance of disseminat-
ng speciﬁc information to the general public, in order to
aise awareness about the disease and its related problems
nd implications.
ypes of approach
s indicated above, ICVD centers should adopt a global
pproach, not only to the patient but also to his or her
amily, considering the familial inheritance of ICVD and the
arious problems involved (clinical, social, legal, and psy-
hological).
ndividual approach
n ICVD centers two groups of patients are expected to be
ollowed: those followed in the center, and patients fol-
owed in other institutions but occasionally referred to the
CVD center for a second opinion or to perform additional
iagnostic tests.
T
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iN. Cardim et al.
Clinical evaluation of patients in the center will include
enetic study and a broad phenotypic characterization with
tratiﬁcation of risk for sudden death every two years. It will
lso include education, genetic counseling and individual-
zed therapy (including general measures, lifestyle, medical
reatment, surgery, septal ablation, deﬁbrillators and pace-
akers).
amily-based approach
he ICVD center also has the task of studying the ICVD
atient’s family in ‘‘family consultations’’, providing the
ogistical basis for a complete genotypic and phenotypic
tudy of the whole family, in a comprehensive approach.
ascade screening (genetic and/or clinical) appears to be
he most cost-effective approach12. Special attention should
e paid to the possible need for psychological support and
o the state of mutation carriers.
rganizational models1,10,11
t is important to realize that not all specialized groups
hould expect to establish an ICVD center. It is unlikely that
mall clinics or departments could develop the necessary
ritical mass to gain sufﬁcient experience of these condi-
ions and to justify the investment in professional training
medical, pathology, genetic counseling, specialist nursing,
aboratory, and cardiac physiology) and organizational struc-
ures to develop into a fully comprehensive service.
The most successful organizational model is the ‘‘hub
nd spoke’’ model. In this model, referrals coming from the
eriphery (spokes) are directed to the specialist tertiary ser-
ice (hub). Once patients have been assessed by the hub,
uch of the patient care may be returned to the spokes
ccording to agreed care guidelines.
Another possibility is the ‘‘specialist and satellite’’
odel. In this model specialist centers have satellites
n peripheral clinics to enable greater ease of access
y patients who live far from the specialist center.
elemedicine may have an important role in this model.
ooperative links1,10,11
he ICVD center should propose the establishment of
ooperation protocols with other institutions dealing with
nherited cardiovascular diseases, including working groups
n myocardial and pericardial diseases of national cardi-
logy societies, national institutes of forensic and sports
edicine, universities and colleges (schools of medicine,
harmacology, etc.), the Working Group on Myocardial and
ericardial Diseases of the European Society of Cardiology,
ther national and international ICVD centers, and other
ntities connected in any way with ICVD, such as patient
upport groups.
onclusionshe prevalence, complexity, clinical importance, hetero-
eneity and unpredictability of inherited cardiovascular dis-
ases make the development of ICVD centers an inevitabil-
ty, with the ultimate goal of reducing the morbidity and
diova
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mortality associated with these conditions. An ICVD cen-
ter may be seen as a subunit of a cardiology department,
with health professionals specializing in these types of
disorders, organized to provide excellence in all related
areas, including diagnosis, treatment, follow-up, preven-
tion, risk stratiﬁcation and prognosis. Among its objectives
are the development of action protocols and the creation of
databases that enable patients to be included in national and
international research networks. To achieve these objec-
tives these centers should include functional units of clinical
and basic sciences, research, training and education, act-
ing in harmony in a holistic approach to patients and their
families.
As most experience on inherited cardiovascular dis-
eases is based on hypertrophic cardiomyopathy and on
‘‘hypertrophic cardiomyopathy centers’’, these centers rep-
resent an excellent opportunity to learn how to set up
inherited cardiovascular disease centers.
European ICVD centers will differ from country to coun-
try, reﬂecting the heterogeneity of national health systems,
but will share a common core presented in this document.
Though we are aware that this ambitious project is not at all
easy and may be difﬁcult to implement in its entirety -- in
fact we consider it a major step -- our position is that all the
efforts to achieve it are worthwhile, considering that the
main goal will always be the well-being of those affected by
these particular disorders.
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